A number of clinical studies have demonstrated that patients with high-risk squamous-cell carcinoma of the head and neck benefit from the addition of EGFR inhibitors to chemotherapy and radiotherapy. The rationale for using targeted therapies based on inhibition of EGFR and angiogenesis, and the most recent pre–clinical and clinical evidence for the role of these agents in the management of head and neck cancers is discussed.
- Jacques Bernier
- Søren M. Bentzen
- Jan B. Vermorken
